Talphera (NASDAQ:TLPH – Get Free Report) and Supreme Cannabis (OTCMKTS:SPRWF – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.
Insider and Institutional Ownership
37.7% of Talphera shares are owned by institutional investors. 3.5% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings for Talphera and Supreme Cannabis, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Talphera | 1 | 1 | 2 | 0 | 2.25 |
| Supreme Cannabis | 0 | 0 | 0 | 0 | 0.00 |
Valuation & Earnings
This table compares Talphera and Supreme Cannabis”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Talphera | $30,000.00 | 2,058.70 | -$14.29 million | ($0.27) | -4.41 |
| Supreme Cannabis | N/A | N/A | N/A | N/A | N/A |
Supreme Cannabis has lower revenue, but higher earnings than Talphera.
Profitability
This table compares Talphera and Supreme Cannabis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Talphera | N/A | -87.28% | -51.36% |
| Supreme Cannabis | N/A | N/A | N/A |
Summary
Talphera beats Supreme Cannabis on 6 of the 8 factors compared between the two stocks.
About Talphera
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
About Supreme Cannabis
The Supreme Cannabis Company, Inc. engages in the production of medical cannabis products in Canada. The company was formerly known as Supreme Pharmaceuticals Inc. and changed its name to The Supreme Cannabis Company, Inc. in December 2017. The Supreme Cannabis Company, Inc. was incorporated in 1979 and is headquartered in Toronto, Canada.
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.
